A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (NCT05704634)

🧪 Interventions in This Study

• Cemiplimab (DRUG)
• Kevzara (Sarilumab) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Cancer

• Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
• Early Detection of Lung Cancer — Nashville, Tennessee
• Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
• Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
• Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
• Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts

Explore by condition: All Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.